This article discusses research done on the efficacy of tamoxifen in preventing the development of breast cancer. it references a study by U. Veronesi and colleagues in a 1998 issue of "Lancet." An antiestrogen, tamoxifen has been effective in reducing the risk of developing breast cancer. The...
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16(1): 67-75.Cuzick, J., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., Howell, A., & Forbes, J. F. (2015). Tamoxifen for prevention of...
Natl. Cancer Inst. 90 (1998) 1371-1388.Bruzzi P. Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue [Editorial]. BMJ. 1998; 316:1181-2. [PMID: 9552991]Bruzzi P. Tamoxifen for the prevention of breast cancer. Important ...
The lifesaving benefit of taking tamoxifen to treat early breast cancer lasts for at least a decade, but only if the drug is used for five years and no longer, two studies showed. The research, published in the Journal of the National Cancer Institute, found that women who took tamoxifen ...
Smith, I. Adjuvant tamoxifen for early breast cancer. Br J Cancer 57, 527–528 (1988). https://doi.org/10.1038/bjc.1988.122 Download citation Issue Date01 December 1988 DOIhttps://doi.org/10.1038/bjc.1988.122 Springer Nature Limited Share this article Anyone you share the following link with...
The article discusses research being done on the effects of Tamoxifen and raloxifene, on breast-cancer patients in Japan. It references a study by M. Kondi, S.-L. Hoshi and M. Toi, published in the January 27, 2009 issue of the "British Journal of Cancer." It was found that ...
The case for tamoxifen to be tested as a preventive for breast cancer has merit. Animal studies demonstrate that tamoxifen prevents mammary carcinogenesis and clinical studies now confirm that adjuvant tamoxifen therapy is the only systemic treatment that will prevent contralateral breast cancer. Developin...
SUGGESTED for you The first report on the cohort, at a median follow-up of 13.9 years, showed that tamoxifen significantly increased recurrence-free survival in patients with ER-positive or progesterone receptor (PR)-positive breast cancer (relative risk [RR], 0.65; 95% confidence interval [CI...
Here, Siziopikou and Cobleigh suggest that the basal subtype of breast carcinomas might be a candidate for therapies targeted against EGFR. The authors found that, of 271 consecutive patients with breast cancer, 48 had tumors that expressed the cytokeratin CK5/6—defined as being of the basal...
To determine the efficacy of tamoxifen as primary treatment for elderly breast cancer patients with locoregional disease, the medical records of 85 patient... L Bergman,JAV Dongen,BV Ooijen,... - 《Breast Cancer Research & Treatment》 被引量: 107发表: 1995年 Tamoxifen may be an effective adj...